If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Pulmonary rehabilitation has established itself as a vital and core therapy for people with chronic lung disease. Significant improvements are seen in several patient outcomes, for the thousands ...

Background Nocturnal hypoxia is prevalent in chronic obstructive pulmonary disease (COPD) and contributes significantly to poor disease prognosis. However, its key environmental risk factors and ...

Background Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV ...

A 71-year-old man presented to the emergency department with sudden onset sharp left-sided chest pain following a severe coughing episode. He was an ex-smoker with a background of chronic obstructive ...

Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, ...

Background The diagnosis and management of pneumonia is often challenging due to its overlapping clinical presentations with other respiratory illnesses, low pathogen identification rates, and slow ...

Background Minimising hypoxaemia during submaximal walking tests has a positive effect on exercise capacity and dyspnoea in patients with chronic obstructive pulmonary disease (COPD) on long-term ...

In this issue of Thorax , Czepiel et al report the results of a double-blind randomised controlled trial of an oral agent, hymecromone, in patients with pulmonary hypertension (PH).1 The authors ...

In this issue of Thorax , the REMAP-CAP investigators publish the final results from the COVID-19 Immune Modulation Therapy Domain for COVID-19 of Randomized, Embedded, Multifactorial Adaptive ...